Out-licensing: Alzheimer´s Transdermal Patch

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

3-day transdermal system for treatment of Alzheimer´s disease

acetylcholinesterase inhibitor | transdermal administration

Labtec is developing a transdermal patch for the continuous treatment of Alzheimer´s disease for 3 days.

Preclinical

undisclosed

Worldwide licensing rights available.

N/A

Dr Ingo Lehrke
Managing Director; Business Development

Labtec GmbH

Labtec GmbH provides innovative Product Development and Manufacturing Services all over the world.

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Therapeutic target: Central Nervous System / Neurodegenerative disorders / Alzheimer's disease; Central Nervous System / Neurodegenerative disorders

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.